Normal view

  • ✇PetaPixel
  • Huge Batch of Lexar Memory Cards Are up to 70% Off, Actually Making Them Affordable Kate Garibaldi
    Spring isn’t just bringing new gear cycles, it’s also delivering some of the most aggressive memory card discounts we’ve seen in a long time. Across Lexar’s CFexpress, SD, and microSD lineup, prices have dropped sharply, often paired with additional in-cart coupons that push savings even further. In some cases, these feel less like routine promotions and more like a temporary reset in the memory card market. [Read More]
     

Huge Batch of Lexar Memory Cards Are up to 70% Off, Actually Making Them Affordable

4 May 2026 at 21:11

Four Lexar Professional memory cards of different sizes and types are displayed against a vibrant background with orange and blue flames. The cards show capacities of 256GB, 1TB, and 4TB with various speed ratings.

Spring isn’t just bringing new gear cycles, it’s also delivering some of the most aggressive memory card discounts we’ve seen in a long time. Across Lexar’s CFexpress, SD, and microSD lineup, prices have dropped sharply, often paired with additional in-cart coupons that push savings even further. In some cases, these feel less like routine promotions and more like a temporary reset in the memory card market.

[Read More]

  • ✇TheHill - Just In
  • FDA moves to fast-track review of 3 psychedelic drug studies Nathaniel Weixel
    The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest step by the Trump administration toward possible approval. The agency did not disclose the specific companies that were granted priority review vouchers. Two companies are studying psilocybin; one for treatment-resistant depression (TRD) and the other for treatment of major depressive disorder.  A t
     

FDA moves to fast-track review of 3 psychedelic drug studies

24 April 2026 at 18:06
The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest step by the Trump administration toward possible approval. The agency did not disclose the specific companies that were granted priority review vouchers. Two companies are studying psilocybin; one for treatment-resistant depression (TRD) and the other for treatment of major depressive disorder.  A third...

❌
Subscriptions